Sun Pharmaceutical Industries Limited Appoints Richard Ascroft as CEO North America

Published: 2025-06-25 15:35:20 ET SUNPHARMA.NS

Published on 06/25/2025 at 15:35

Sun Pharmaceutical Industries Limited announced the appointment of Richard Ascroft as its new North America Chief Executive Officer (CEO), effective June 16, 2025. Richard brings over three decades of experience in the pharmaceutical industry, with a proven record of leadership, innovation, and strategic growth. As North America CEO, Richard will advance Sun Pharma's diverse portfolio of innovative medicines, generics and over-the-counter products in both the U.S. and Canada.

With a background spanning commercial, market access, clinical development and corporate affairs across the U.S. and global markets, Richard's expertise and vision will be instrumental in guiding the continued growth of the Sun Pharma North America business, including the innovative medicines portfolio which has upcoming commercial launches of new treatments for alopecia areata and squamous cell carcinoma. Richard is succeeding Abhay Gandhi who played a pivotal role in the growth of the Sun Pharma North America business and will report into Aalok Shanghvi, Sun Pharma's whole-time Director and Chief Operating Officer. Richard joins Sun Pharma from Takeda Pharmaceuticals where he most recently served as Senior Vice President and Business Unit Head of U.S. Plasma-Derived Therapies and was a member of both the U.S. and global executive leadership teams.